1,5,5-trimethyl-3-(4-(2-oxo-8-n-propyl-4-(trifluoromethyl)-2H-chromen-7-yloxy)butyl)imidazolidine-2,4-dione | 1186115-78-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 1,5,5-trimethyl-3-(4-(2-oxo-8-n-propyl-4-(trifluoromethyl)-2H-chromen-7-yloxy)butyl)imidazolidine-2,4-dione
• 英文别名: 1,5,5-trimethyl-3-[4-[2-oxo-8-propyl-4-(trifluoromethyl)-2H-chromen-7-yloxy]butyl]imidazolidine-2,4-dione；1,5,5-trimethyl-3-[4-[2-oxo-8-propyl-4-(trifluoromethyl)chromen-7-yl]oxybutyl]imidazolidine-2,4-dione
• CAS: 1186115-78-5
• 化学式: C₂₃H₂₇F₃N₂O₅
• 分子量: 468.473
• InChiKey: AIPZKNVPWAZNKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  76.2
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-正丙基间苯二酚 在 potassium carbonate 、 zinc(II) chloride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 34.0h， 生成 1,5,5-trimethyl-3-(4-(2-oxo-8-n-propyl-4-(trifluoromethyl)-2H-chromen-7-yloxy)butyl)imidazolidine-2,4-dione
  参考文献：
  名称：

  设计和发现2-氧代色烯衍生物作为肝X受体β选择性激动剂

  摘要：

  在分子设计肝X受体（LXR）β-选择性激动剂的尝试中，我们发现2-氧代色烯部分（头部）和咪唑啉-2,4-二酮部分（尾巴）的组合在表达能力和对LXRβ的选择性。我们合成了一系列2-oxochromene衍生物，并确定了43种LXRβ选择性激动剂，可在不显着升高TG水平的情况下增加HDL-C水平，并导致高脂饮食中主动脉弓内脂质蓄积面积减少。和胆固醇喂养的Bio F 1 B仓鼠。在这份手稿中，我们报告了这些2-氧代苯并二氢吡喃衍生物的设计，合成和药理作用。

  DOI：

  10.1016/j.bmcl.2015.01.047

文献信息

• 2-OXOCHROMENE DERIVATIVES
  申请人：OKUDA Ayumu

  公开号：US20090286780A1

  公开（公告）日：2009-11-19

  To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A 2-oxochromene derivative represented by the following general formula (1) or salt thereof, or their solvate.

  提供一种新型的LXRβ激动剂，可用作预防和/或治疗动脉粥样硬化；动脉硬化，如糖尿病引起的动脉硬化；血脂异常；高胆固醇血症；与脂质相关的疾病；由炎性细胞因子引起的炎症性疾病；皮肤疾病，如过敏性皮肤病；糖尿病；或阿尔茨海默病。[解决方法]由下面的一般式（1）所表示的2-氧代色素衍生物或其盐，或它们的溶剂化合物。
• 2-oxochromene derivatives
  申请人：Kowa Company, Ltd.

  公开号：US07919509B2

  公开（公告）日：2011-04-05

  To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A 2-oxochromene derivative represented by the following general formula (1) or salt thereof, or their solvate.

  提供一种新型的LXRβ激动剂，可用作预防和/或治疗动脉粥样硬化、动脉硬化（例如由糖尿病引起的动脉硬化）、血脂异常、高胆固醇血症、与脂质相关的疾病、由炎症细胞因子引起的炎症性疾病、过敏性皮肤病、糖尿病或阿尔茨海默病的预防和/或治疗剂。[解决方法] 以下一般式（1）所表示的2-氧基色酮衍生物或其盐，或其溶剂。
• 2-OXOCHROMENE DERIVATIVE
  申请人：Kowa Company, Ltd.

  公开号：EP2248811A1

  公开（公告）日：2010-11-10

  [Object] It is to provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes;dyslipidemia; hypercholesterolemia; lipid-reflated diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. A 2-oxochromene derivative represented by the following general formula (1) or salt thereof, or their solvate.

  目的 提供一种新型LXRβ激动剂，该激动剂可作为动脉粥样硬化、动脉硬化（如糖尿病引起的动脉硬化）、血脂异常、高胆固醇血症、血脂膨胀性疾病、由炎症细胞因子引起的炎症性疾病、皮肤病（如过敏性皮肤病）、糖尿病或阿尔茨海默病的预防和/或治疗药物。由以下通式（1）代表的 2-氧代二氢苯衍生物或其盐，或它们的溶解物。
• US7919509B2
  申请人：——

  公开号：US7919509B2

  公开（公告）日：2011-04-05
• Design and discovery of 2-oxochromene derivatives as liver X receptor β-selective agonists
  作者：Takayuki Matsuda、Ayumu Okuda、Yuichiro Watanabe、Tohru Miura、Hidefumi Ozawa、Ayako Tosaka、Koichi Yamazaki、Yuki Yamaguchi、Sayaka Kurobuchi、Minoru Koura、Kimiyuki Shibuya

  DOI：10.1016/j.bmcl.2015.01.047

  日期：2015.3

  an attempt to molecularly design liver X receptor (LXR) β-selective agonists, we discovered that the combination of the 2-oxochromene moiety (head) and the imidazoline-2,4-dione moiety (tail) plays an important role in the expression potency and selectivity toward LXRβ. We synthesized a series of 2-oxochromene derivatives and identified 43 as a LXRβ-selective agonist that increased the HDL-C level without

  在分子设计肝X受体（LXR）β-选择性激动剂的尝试中，我们发现2-氧代色烯部分（头部）和咪唑啉-2,4-二酮部分（尾巴）的组合在表达能力和对LXRβ的选择性。我们合成了一系列2-oxochromene衍生物，并确定了43种LXRβ选择性激动剂，可在不显着升高TG水平的情况下增加HDL-C水平，并导致高脂饮食中主动脉弓内脂质蓄积面积减少。和胆固醇喂养的Bio F 1 B仓鼠。在这份手稿中，我们报告了这些2-氧代苯并二氢吡喃衍生物的设计，合成和药理作用。